Contact
Please use this form to send email to PR contact of this press release:
Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
TO:
Please use this form to send email to PR contact of this press release:
Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
TO: